PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 163 filers reported holding PDL BIOPHARMA INC in Q2 2018. The put-call ratio across all filers is 1.66 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $3,558,000 | +3.1% | 1,129,470 | -4.8% | 0.04% | 0.0% |
Q2 2020 | $3,452,000 | +0.6% | 1,186,100 | -2.5% | 0.04% | -22.4% |
Q1 2020 | $3,431,000 | -4.7% | 1,216,690 | +9.7% | 0.06% | +45.0% |
Q4 2019 | $3,599,000 | +50.6% | 1,109,145 | +0.3% | 0.04% | +42.9% |
Q3 2019 | $2,389,000 | -38.8% | 1,105,970 | -11.0% | 0.03% | -37.8% |
Q2 2019 | $3,903,000 | -16.1% | 1,243,125 | -0.6% | 0.04% | -23.7% |
Q1 2019 | $4,650,000 | +30.2% | 1,250,040 | +1.5% | 0.06% | +15.7% |
Q4 2018 | $3,572,000 | +12.2% | 1,231,730 | +1.7% | 0.05% | +54.5% |
Q3 2018 | $3,185,000 | +12.4% | 1,211,150 | 0.0% | 0.03% | +6.5% |
Q2 2018 | $2,834,000 | -20.4% | 1,211,150 | -0.0% | 0.03% | -26.2% |
Q1 2018 | $3,561,000 | +0.2% | 1,211,300 | -6.6% | 0.04% | -2.3% |
Q4 2017 | $3,555,000 | -38.4% | 1,297,300 | -23.8% | 0.04% | -39.4% |
Q3 2017 | $5,768,000 | +36.6% | 1,701,500 | -0.5% | 0.07% | +29.1% |
Q2 2017 | $4,222,000 | +163.9% | 1,709,500 | +142.6% | 0.06% | +150.0% |
Q1 2017 | $1,600,000 | – | 704,800 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |